Ovation ScienceOVATF EV-to-EBITDA is -1.70 as of Jul. 13, 2026. The stock has 4 warning signs investors should review. Among 739 Drug Manufacturers companies, Ovation Science ranks worse than 135317.86% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Ovation Science's enterprise value is $0.72 Mil.
Ovation Science's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.42 Mil. Therefore, Ovation Science's EV-to-EBITDA for today is -1.70.
The historical rank and industry rank for Ovation Science's EV-to-EBITDA or its related term are showing as below:
OVATF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -31.67 Med: -2.81 Max: -0.17
Current: -1.75
During the past 9 years, the highest EV-to-EBITDA of Ovation Science was -0.17. The lowest was -31.67. And the median was -2.81.
OVATF's EV-to-EBITDA is ranked worse than 100% of 739
companies
in the Drug Manufacturers industry
Industry Median: 12.99
vs OVATF: -1.75
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Ovation Science's PE Ratio (TTM) for today is calculated as:
Ovation Science's share price for today is $0.035.
Ovation Science's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.007.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Ovation Science's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Ovation Science's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ovation Science EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ovation Science's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Ovation Science's EV-to-EBITDA falls into.
Ovation Science's current Enterprise Value is $0.72 Mil.
Ovation Science's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.42 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ovation Science (OVATF) has a EV-to-EBITDA of -1.70 as of Jul. 13, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Ovation Science. According to the industry distribution chart, Ovation Science ranks #999999 out of 739 companies in the Drug Manufacturers industry.
Is Ovation Science's EV-to-EBITDA too high?
Ovation Science's current EV-to-EBITDA is -1.70. Based on the distribution chart, Ovation Science ranks #999999 out of 739 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Ovation Science's EV-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Ovation Science ranks #999999 out of 739 companies for EV-to-EBITDA. This places Ovation Science in the lower half of its industry. The industry median EV-to-EBITDA is 12.99. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 12.99, based on 739 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Ovation Science. For the Drug Manufacturers industry, the median EV-to-EBITDA is 12.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ovation Science's current EV-to-EBITDA is -1.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ovation Science stock overvalued right now?
Ovation Science (OVATF) has a current EV-to-EBITDA of -1.70. The stock's GF Value™ is $0.04, compared to a current price of $0.04 — trading 12.5% below its estimated fair value. The current EV-to-EBITDA is -1.70. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Ovation Science (OVATF), the current EV-to-EBITDA is -1.70 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Ovation Science Inc. is a Canada-based company mainly engaged in the business of providing topical and transdermal cannabis products under the Ovation brand label, utilizing patented Invisicare delivery technology. The Company operates in one reportable operating segment, the sub-licensing and sales of cannabis products that utilize Invisicare, a patented polymer-based technology for topical and transdermal skin care products.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OVATF has been successfully added to your 